BioAge Labs, Inc. Common Stock (BIOA)

Price$17.20

Value ScoreD

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)85.35%

Price vs S&P 500 (4W)-1.99%

VGM Score60.52

Market Capitalization$768.59M

All Metrics

Book Value / Share (Quarterly)$8.54

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.00

Price vs S&P 500 (YTD)19.75%

Net Profit Margin (TTM)-871.75%

EPS (TTM)$-2.40

10-Day Avg Trading Volume0.48M

EPS Excl Extra (TTM)$-2.40

EPS (Annual)$-2.24

ROI (Annual)-29.34%

Cash / Share (Quarterly)$8.63

Revenue Growth QoQ (YoY)91.04%

ROA (Last FY)-27.33%

EBITD / Share (TTM)$-2.70

Operating Margin (TTM)-985.93%

Cash Flow / Share (Annual)$-2.20

P/B Ratio2.03x

P/B Ratio (Quarterly)2.05x

Net Income / Employee (Annual)$-1,343,400

EV / Revenue (TTM)51.18x

Net Interest Coverage (TTM)-10.91x

ROA (TTM)-27.26%

EPS Incl Extra (Annual)$-2.24

Current Ratio (Annual)14.24x

Quick Ratio (Quarterly)24.26x

3-Month Avg Trading Volume0.55M

52-Week Price Return334.42%

Revenue / Employee (TTM)$171,900

P/S Ratio (Annual)85.45x

Asset Turnover (Annual)0.03x

52-Week High$24.00

EPS Excl Extra (Annual)$-2.24

26-Week Price Return101.28%

Quick Ratio (Annual)14.00x

13-Week Price Return-22.54%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)24.76x

Enterprise Value$527.97M

Asset Turnover (TTM)0.03x

Revenue / Employee (Annual)$149,900

Pretax Margin (Annual)-896.11%

Cash / Share (Annual)$7.52

3-Month Return Std Dev82.32%

Net Income / Employee (TTM)$-1,498,800

ROE (Last FY)-29.63%

EPS Basic Excl Extra (Annual)$-2.24

Receivables Turnover (TTM)19.28x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.40

ROI (TTM)-29.08%

P/S Ratio (TTM)74.50x

Revenue / Share (Annual)$0.25

Price vs S&P 500 (52W)306.22%

Year-to-Date Return30.69%

5-Day Price Return4.09%

EPS Normalized (Annual)$-2.24

Net Profit Margin (Annual)-896.11%

Month-to-Date Return2.61%

EBITD / Share (Annual)$-2.58

Operating Margin (Annual)-1031.46%

LT Debt / Equity (Annual)0.00x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.40

P/B Ratio (Annual)1.74x

Pretax Margin (TTM)-871.75%

Book Value / Share (Annual)$7.28

Price vs S&P 500 (13W)-32.28%

Beta1.70x

Revenue / Share (TTM)$0.24

ROE (TTM)-29.40%

52-Week Low$3.88

vGradeD

gGradeA

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.52est. -0.65

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.91

4.17

4.15

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
BIOABioAge Labs, Inc. Common Stock	D	A	B	$17.20
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Bioage Labs is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases like obesity by targeting the biology of aging. Its pipeline includes NLRP3 inhibitors and APJ agonists designed to address the underlying mechanisms of age-related metabolic dysfunction.